[go: up one dir, main page]

ATE324441T1 - Htk-ligand - Google Patents

Htk-ligand

Info

Publication number
ATE324441T1
ATE324441T1 AT95926279T AT95926279T ATE324441T1 AT E324441 T1 ATE324441 T1 AT E324441T1 AT 95926279 T AT95926279 T AT 95926279T AT 95926279 T AT95926279 T AT 95926279T AT E324441 T1 ATE324441 T1 AT E324441T1
Authority
AT
Austria
Prior art keywords
ligand
htk
ligands
htk ligand
receptor
Prior art date
Application number
AT95926279T
Other languages
English (en)
Inventor
Brian D Bennett
William Matthews
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23062090&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE324441(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE324441T1 publication Critical patent/ATE324441T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT95926279T 1994-07-20 1995-07-14 Htk-ligand ATE324441T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US27772294A 1994-07-20 1994-07-20

Publications (1)

Publication Number Publication Date
ATE324441T1 true ATE324441T1 (de) 2006-05-15

Family

ID=23062090

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95926279T ATE324441T1 (de) 1994-07-20 1995-07-14 Htk-ligand

Country Status (11)

Country Link
US (2) US5864020A (de)
EP (1) EP0773997B2 (de)
JP (1) JPH10501701A (de)
AT (1) ATE324441T1 (de)
AU (1) AU705107B2 (de)
CA (1) CA2194955A1 (de)
DE (1) DE69534962T3 (de)
ES (1) ES2264127T5 (de)
IL (1) IL114668A (de)
MX (1) MX9700486A (de)
WO (1) WO1996002645A2 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932214A (en) * 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
US6303769B1 (en) * 1994-07-08 2001-10-16 Immunex Corporation Lerk-5 dna
WO1996026958A2 (en) * 1995-02-27 1996-09-06 President And Fellows Of Harvard College Eph RECEPTOR LIGAND ELF-2
AU716889B2 (en) 1995-11-17 2000-03-09 Asahi Kasei Kogyo Kabushiki Kaisha Differentiation-suppressive polypeptide
DE69736109T2 (de) 1996-07-16 2007-01-04 Asahi Kasei Kabushiki Kaisha Differenzierungsinhibitor
AUPO754997A0 (en) * 1997-06-25 1997-07-17 Leukaemia Foundation Of Queensland, The Receptor-ligand system and assay therefor
WO1999017796A2 (en) 1997-10-02 1999-04-15 Leukosite, Inc. Modulation of lerk-2-mediated cell adhesion
US6864227B1 (en) * 1998-04-13 2005-03-08 California Institute Of Technology Artery-and vein-specific proteins and uses therefor
US6887674B1 (en) * 1998-04-13 2005-05-03 California Institute Of Technology Artery- and vein-specific proteins and uses therefor
PT1135153E (pt) * 1998-11-20 2005-09-30 Genentech Inc Utilizacoes para antagonistas e agonistas de receptores eph para tratar desordens vasculares
US7171263B2 (en) * 1999-06-04 2007-01-30 Impulse Dynamics Nv Drug delivery device
EP1978110B1 (de) * 2000-09-06 2010-05-26 Transnetyx, Inc. Computer-basiertes Verfahren und System zum Screenen von genomischer DNS
WO2002026827A1 (en) * 2000-09-29 2002-04-04 Novartis Ag Extracellular polypeptides of eph b receptors and ephrin b ligands and the corresponding nucleic acid molecules
US20050152899A1 (en) * 2002-05-10 2005-07-14 Kinch Michael S. EphA2 agonistic monoclonal antibodies and methods of use thereof
JP4557714B2 (ja) * 2002-05-10 2010-10-06 メディミューン，エルエルシー ＥｐｈＡ２モノクローナル抗体およびその使用法
CA2485548A1 (en) * 2002-05-10 2004-02-19 Purdue Research Foundation Epha2 agonistic monoclonal antibodies and methods of use thereof
MXPA05001364A (es) * 2002-08-02 2005-08-03 Wyeth Corp Proteinas de interaccion de mk2.
EP1553963A4 (de) * 2002-09-24 2006-05-03 Burnham Inst NEUE MITTEL ZUR MODULIERUNG DER EPH-REZEPTOR-AKTIVITûT
US7381410B2 (en) * 2003-03-12 2008-06-03 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
AU2004220459B2 (en) * 2003-03-12 2010-08-05 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
EP1617864A4 (de) * 2003-04-11 2006-06-21 Medimmune Inc Epha2 und nicht-neoplastische hyperproliferative zellstörungen
EP1618184A4 (de) * 2003-04-11 2006-06-21 Medimmune Inc Epha2, hydroproliferative zellstörungen sowie epithel- und endothel-rekonstituierung
KR20120123619A (ko) 2004-03-12 2012-11-08 바스진 테라퓨틱스, 인크. 혈관형성 및 종양 성장을 억제하기 위한 폴리펩티드 화합물
EP2275445A3 (de) * 2004-03-12 2012-02-29 Vasgene Therapeutics, Inc. Ephb4-bindende Antikörper zur Inhibierung von Angiogenese und Tumorwachstum
EP1602928A1 (de) * 2004-06-01 2005-12-07 Universiteit Maastricht Verfahren und Kit zur Bestimmung der Bindungsparameter von Bioaffinitätsbindungsreaktionen
CA2581423A1 (en) * 2004-09-23 2006-03-30 Vasgene Therapeutics, Inc. Polipeptide compounds for inhibiting angiogenesis and tumor growth
EP1799867A2 (de) * 2004-09-23 2007-06-27 Vasgene Therapeutics, Inc. Zusammensetzungen und verfahren zur erkennung und behandlung von tumoren
AU2006208068B2 (en) * 2005-01-27 2011-08-04 The Burnham Institute EphB receptor-binding peptides
US20070218061A1 (en) * 2005-09-23 2007-09-20 Vasgene Therapeutics, Inc. Use of ephrinb2 directed agents for the treatment or prevention of viral infections
JPWO2007043629A1 (ja) * 2005-10-05 2009-04-16 アキュメンバイオファーマ株式会社 エフリンｂ２を用いる血管新生の抑制方法
US8101365B2 (en) * 2006-01-05 2012-01-24 Genentech, Inc. Anti-EphB4 antibodies and methods using same
AU2008287427B2 (en) * 2007-08-13 2014-10-09 Vasgene Therapeutics, Inc. Cancer treatment using humanized antibodies that bind to EphB4
EP3144320B9 (de) * 2011-04-13 2018-08-22 Bristol-Myers Squibb Company Fc-fusionsproteine mit neuartigen linkern oder anordnungen
JP6158090B2 (ja) * 2011-10-31 2017-07-05 ダニエル・ジェイ・カポン 非ペプチドヒンジ部含有フレキシブル抗体様分子

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07504813A (ja) * 1992-01-22 1995-06-01 ニユー・イングランド・デイーコネス・ホスピタル 新規蛋白質チロシンキナーゼ類
US5635177A (en) * 1992-01-22 1997-06-03 Genentech, Inc. Protein tyrosine kinase agonist antibodies
JP3560609B2 (ja) * 1992-11-13 2004-09-02 イミュネックス・コーポレーション Ｅｌｋリガンドと呼ばれる新規なサイトカイン
AU691915B2 (en) * 1994-04-04 1998-05-28 Regeneron Pharmaceuticals, Inc. Biologically active EPH family ligands
US6303769B1 (en) * 1994-07-08 2001-10-16 Immunex Corporation Lerk-5 dna

Also Published As

Publication number Publication date
DE69534962D1 (en) 2006-06-01
WO1996002645A2 (en) 1996-02-01
ES2264127T3 (es) 2006-12-16
EP0773997A2 (de) 1997-05-21
JPH10501701A (ja) 1998-02-17
DE69534962T3 (de) 2012-10-04
CA2194955A1 (en) 1996-02-01
EP0773997B2 (de) 2012-04-25
ES2264127T5 (es) 2012-07-04
IL114668A0 (en) 1995-11-27
EP0773997B1 (de) 2006-04-26
WO1996002645A3 (en) 1996-02-15
MX9700486A (es) 1997-04-30
US5864020A (en) 1999-01-26
AU705107B2 (en) 1999-05-13
IL114668A (en) 2007-07-24
AU3008995A (en) 1996-02-16
DE69534962T2 (de) 2007-02-08
US5624899A (en) 1997-04-29

Similar Documents

Publication Publication Date Title
ATE324441T1 (de) Htk-ligand
NO961115D0 (no) Humane metabotrope glutamatreseptorsubtyper (HMR4, HMR6, HMR7) og relaterte DNA forbindelser
FI20022285L (fi) Eristetty liukoinen CTL4A-proteiini, sitä sisältäviä fuusioproteiineja, sen ligandeja, sen tunnistavia monoklonaalisia vasta-aineita ja käyttötapoja
PT822199E (pt) Polipeptidos monopegilados no terminal-n e metodo para a sua preparacao
EP1308461A3 (de) Antikörper gegen Beta-Amyloiden oder deren Abarten, und deren Verwendungen
DK0784683T3 (da) TIE-2-ligander, fremgangsmåder til dannelse af disse og anvendelser deraf
SG96535A1 (en) Pharmaceutical composition for the treatment or prevention of a malignant tumor
ATE309360T1 (de) Vaskularer endothelialer wachstumsfaktor 2
ATE170630T1 (de) Proteine mit geänderten epitopen und verfahren zur deren herstellung
NO964650D0 (no) LAG-3 protein-opplöselige polypeptidfraksjoner, fremgangsmåte for fremstilling, teraupeutisk preparat og anti-idiotype antistoff
ATE167896T1 (de) Aus mehreren domänen bestehende hämatopoese- stimulatoren
HK1008230A1 (en) Tie-2 ligands, methods of making and uses thereof.
GR3036906T3 (en) Monoclonal antibody which specifically binds to tumor vascular endothelium and uses thereof.
NZ512083A (en) Methods of increasing lean tissue mass using OB protein compositions
YU79491A (sh) Varijantni cd44-površinski proteini, dna-sekvence koje ih kodiraju i antitela protiv ovih proteina
IT1207589B (it) Composizione di anticorpi monoclonali umani cross-protettivi.
PT877803E (pt) Receptor da proteina ob e composicoes e metodos afins
EP0854185A3 (de) Rezeptor-Proteine zu Bestimmungszwecke und Liganden
ATE164838T1 (de) Neue propoxyphenderivate sowie deren protein-und polypeptidlabels und-konjugate
DE69626829D1 (de) Monoklonale antikörper gegen lösliche tnf-alpha rezeptoren p55 und p75 als auch gegen tnf-alpha und dessen analogen
EP1212340A4 (de) 29 mit krebs im zusammenhang stehende menschliche proteine
WO1999042127A3 (en) Receptor derived peptides as modulators of receptor activity
DE69611037D1 (de) Methadonderivate und protein- und polypeptid-methadonkonjugate und markierte verbindungen
WO1992016623A3 (en) Receptors for bombesin-like peptides
DE59207362D1 (de) Monoklonale Antikörper gegen den Plasmin-Antiplasmin Komplex, Verfahren zu ihrer Herstellung sowie ihre Verwendung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0773997

Country of ref document: EP